Volume 3.25 | Jul 2

Cancer Stem Cell News 3.25 July 2, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
Diabolical Duo: Known Breast Cancer Gene Needs a Partner to Initiate and Spread Tumors
Researchers have revealed that the gene Metadherin – which is implicated in promoting the spread of breast cancer tumors – only stimulates tumor growth when the protein made by the gene interacts with a second protein known as SND1. [Press release from Princeton University discussing online prepublication in Cancer Cell] Press Release | Abstract | Graphical Abstract
NeuroCult™ for Brain Tumor Research - View Publications
 
PUBLICATIONS (Ranked by impact factor of the journal)
Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stem-Like Cells
Researchers showed that afatinib, a small molecule inhibitor of the tyrosine kinases EGFR, HER-2 and HER-4, preferentially eliminated side population cells with cancer stem-like cells character, in both cell lines or patient-derived leukemia cells, by decreasing ABCG2 expression. [Cancer Res] Abstract

Crosstalk between Glioma Initiating Cells and Endothelial Cells Drives Tumor Progression
Researchers report that, in both glioma initiating cells and endothelial cells, platelet derived growth factor-driven activation of nitric oxide (NO) synthase increases NO-dependent inhibitor of differentiation 4 expression, which in turn promotes JAGGED1-NOTCH activity through suppression of miR-129 that specifically represses JAGGED1 suppression. [Cancer Res] Abstract

Targeting the bHLH Transcriptional Networks by Mutated E Proteins in Experimental Glioma
Scientists overexpressed a wildtype or a dominant negative form of E47 that lacks its nuclear localization signal thus preventing nuclear translocation of basic helix-loop-helix (bHLH) proteins in long-term glioma cell lines and in glioma-initiating cell lines and analyzed the effects in vitro and in vivo. [Stem Cells] Abstract

Exosomes from Bone Marrow Mesenchymal Stem Cells Contain a MicroRNA that Promotes Dormancy in Metastatic Breast Cancer Cells
Coculturing BM2 cells with bone marrow mesenchymal stem cells (BM-MSCs) isolated from human donors revealed that BM-MSCs suppressed the proliferation of BM2 cells, decreased the abundance of stem cell-like surface markers, inhibited their invasion through Matrigel Transwells, and decreased their sensitivity to docetaxel, a common chemotherapy agent. [Sci Signal] Abstract

Hedgehog Signaling Sensitizes Glioma Stem Cells to Endogenous Nano-Irradiation
Scientists examined the potential of the Sonic hedgehog ligand for sensitizing of glioma stem cells to endogenous nano-irradiation. They demonstrate that the Sonic hedgehog ligand preferentially and efficiently activated glioma stem cells to enter the radiation sensitive G2/M phase. [Oncotarget] Abstract

Synthetic, Non-Saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells
Scientists developed a tandem, dual screen strategy involving assessing inhibition of monolayer versus spheroid growth and assessing inhibition of primary versus secondary spheroid growth to identify G2.2, a unique sulfated nonsaccharide GAG mimetic from a focused library of 53 molecules, as a selective inhibitor of colon cancer stem-like cells. [ACS Chem Biol] Abstract | Graphical Abstract

Primary Glioblastoma Cultures: Can Profiling of Stem Cell Markers Predict Radiotherapy Sensitivity?
Established stem cell markers and stem cell attributed characteristics such as self-renewal capacity and tumorigenicity have been profiled in primary glioblastoma cultures to predict radiosensitivity. [J Neurochem] Abstract

CTR2 Identifies a Population of Cancer Cells with Stem-Like Features in Patients with Clear Cell-Renal Cell Carcinoma
Scientists aimed to identify and characterize in tissue samples of clear cell-renal cell carcinoma a population of CD133+/CD24+ cancer cells and to study the differences with their non-neoplastic counterpart, tubular adult renal progenitor cells. [J Urol] Abstract

Inhibition of Cdk2 Kinase Activity Selectively Targets the CD44+/CD24/Low Stem-Like Subpopulation and Restores Chemosensitivity of SUM149PT Triple-Negative Breast Cancer Cells
Scientists employed the luminal ER+ MCF-7 and the inflammatory breast cancer SUM149PT breast cancer cell lines to establish the extent to which high grade of chromosomal instability and chemoresistance were mechanistically linked to the enrichment of CD44+/CD24/Low CSCs. [Int J Oncol] Abstract

Tanshinone IIA Inhibits the Growth, Attenuates the Stemness and Induces the Apoptosis of Human Glioma Stem Cells
Researchers aimed to determine the inhibitory effect of tanshinone IIA on human glioma stem cells in vitro and in vivo and explored the underlying mechanisms. [Oncol Rep] Abstract

Wilms’ Tumor Blastemal Stem Cells Dedifferentiate to Propagate the Tumor Bulk
By generating pure blastema Wilms’ tumor (WT) xenografts, composed solely of cells expressing the renal developmental markers SIX2 and neural cell adhesion molecule 1, scientists showed that sorted aldehyde dehydrogenase 1-positive WT cancer stem cells do not correspond to earliest renal stem cells. Rather, gene expression and proteomic comparative analyses disclose a cell type skewed more toward epithelial differentiation than the bulk of the blastema. [Stem Cell Rep] Full Article | Press Release

[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ Watch Now
 
REVIEWS
Evaluating the Immortal Strand Hypothesis in Cancer Stem Cells: Symmetric/Self-Renewal as the Relevant Surrogate Marker of Tumorigenicity
Recent data suggest that cancer stem cells demonstrate a higher incidence of symmetric versus asymmetric cell division with both daughter cells retaining self-renewal characteristics, a profile which may underlie poorly differentiated morphology and marked clonal diversity in tumors. [Biochem Pharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
Merck announced the European Medicines Agency has accepted for review a Marketing Authorization Application for pembrolizumab, the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. [Merck & Co., Inc.] Press Release

Janssen Submits EU Marketing Application for VELCADE® (Bortezomib) in Mantle Cell Lymphoma
Janssen-Cilag International NV announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE® (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma. [Janssen-Cilag International NV] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW BIO Latin America
September 9-11, 2014
Rio de Janeiro, Brazil

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

NEW Postdoctoral Research Associate – Cancer Stem Cell Biology (University of California, San Diego)

NEW PhD Position – Molecular Biology (International PhD Programme)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Assistant/Research Associate – Stem Cell and Cancer Biology (University of North Texas Health Science Center)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

PhD Scholarship – Inorganic Nanoparticles for Cancer Stem Cell Targeting and Detection (The Italian Institute of Technology)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us